Program
recombinant FVIIa
Also written as “activated recombinant human factor VII”, “eptacog alfa (activated)” and “Coagulation Factor VIIa (Recombinant)”.
Its studies are mostly in Hemophilia A · Cerebral Hemorrhage · Wounds and Injuries · Fibrosis · Postpartum Hemorrhage, led by 4 companies.
Drug pageRecombinant FVIIa: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 361 open or running | phase 4since Dec 11, 2007 | Jan 19, 2005 | Aug 26, 2027phase 4 · NCT07157423 |
| Laboratoire français de Fractionnement et de Biotechnologiesits history only | 20 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| rEVO Biologicsits history only | 20 open or running | phase 3since Dec 18, 2013 | Oct 15, 2012 | none ahead |
| AryoGen Pharmed | 10 open or running | phase 3since Mar 4, 2017 | Mar 4, 2017 | none ahead |
Also a collaborator on its studies: LFB USA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AryoGen Pharmed only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2017First study: phase 3 study in Factor VII DeficiencyFirst studyNCT03079063 · 24 enrolled · Iran, Islamic Republic of
TargetBeta
“A recombinant form of the vitamin K-dependent glycoprotein and coagulation factor VIIa (FVIIa), that can be used for the treatment of bleeding episodes and perioperative management in patients with hemophilia, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia”NCIt, by rule
Studies
The one study AryoGen Pharmed leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03079063Factor VII Deficiency · Iran, Islamic Republic of | 3 | Completed | Nov 30, 2020 | 24 |
How it is read
Names in the registry
- “activated recombinant human factor VII”, 32 entries
- “eptacog alfa (activated)”, 12 entries
- “Coagulation Factor VIIa (Recombinant)”, 3 entries
- “Eptacog alfa (NovoSeven)”, 1 entry
- “Eptacog alfa, biosimilar”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 15 studies
- Cerebral Hemorrhage, 5 studies
- Wounds and Injuries, 5 studies
- Fibrosis, 2 studies
- Postpartum Hemorrhage, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.